<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pacritinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pacritinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pacritinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="135300" href="/d/html/135300.html" rel="external">see "Pacritinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56670740"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vonjo</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56628843"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, FLT3 Inhibitor;</li>
<li>
                        Antineoplastic Agent, Janus Associated Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>
<li>
                        Janus Associated Kinase Inhibitor;</li>
<li>
                        Janus Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F56651996"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Taper or discontinue other kinase inhibitors prior to initiating pacritinib. Avoid pacritinib in patients with active bleeding or a baseline QTc of &gt;480 msec. Due to the risk of hemorrhage, withhold pacritinib 7 days prior to elective surgery (or invasive procedures); reinitiate pacritinib only after hemostasis is established. Control preexisting diarrhea prior to pacritinib initiation. Delay initiation of pacritinib therapy until active serious infections have resolved.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="02c97b93-892c-472e-b905-d7209fa55a9f">Myelofibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelofibrosis: Oral: </b>200 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29522138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29522138'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses:</i> If a pacritinib dose is missed, the next scheduled dose should be administered at the scheduled time. Do not administer additional capsules to make up for the missed dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56651998"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> eGFR estimated by MDRD equation.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling; however, C<sub>max</sub> and AUC were similar in subjects with eGFR 30 to 89 mL/minute, compared to subjects with eGFR ≥90 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute: Avoid pacritinib use.</p></div>
<div class="block doha drugH1Div" id="F56651999"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate (Child-Pugh class B) or severe (Child-Pugh class C) impairment: Avoid pacritinib use.</p></div>
<div class="block dot drugH1Div" id="F56652000"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Recommended Pacritinib Dosage Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Initial (starting) dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">First dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Second dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg once daily</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Discontinue pacritinib if unable to tolerate 100 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Recommended Pacritinib Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Toxicity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Pacritinib dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Increase of ≥7 stools/day over baseline, or hospitalization indicated, or severe increase in ostomy output over baseline, or if limits self-care.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Increase of &lt;4 stools/day over baseline or mild increase in ostomy output compared to baseline.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Hematologic toxicity</i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Clinically significant worsening of thrombocytopenia that lasts &gt;7 days</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hold pacritinib until thrombocytopenia resolves, then resume with a 50% dose reduction.</p>
<p style="text-indent:0em;text-align:left;">If thrombocytopenia recurs, hold pacritinib. Once thrombocytopenia resolves, resume pacritinib at 50% of the last administered dose.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Hemorrhage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate bleeding; intervention indicated</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hold pacritinib until hemorrhage resolves, then resume at the last administered dose.</p>
<p style="text-indent:0em;text-align:left;">If hemorrhage recurs, hold pacritinib. Once hemorrhage resolves, resume pacritinib at 50% of the last administered dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe bleeding; transfusion, invasive intervention, or hospitalization indicated</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hold pacritinib until hemorrhage resolves, then resume with a 50% dose reduction.</p>
<p style="text-indent:0em;text-align:left;">If bleeding recurs, discontinue pacritinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Life-threatening bleeding; urgent intervention indicated</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Discontinue pacritinib.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Nonhematologic toxicity</i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cardiac</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">QTc prolongation &gt;500 msec or &gt;60 msec from baseline</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hold pacritinib. If QTc prolongation resolves to ≤480 msec or baseline within 1 week, resume pacritinib at the same dose. If time to resolution is &gt;1 week, resume pacritinib at a reduced dose.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Diarrhea</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">New onset diarrhea</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Initiate antidiarrheal medications and encourage adequate oral hydration.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hold pacritinib until diarrhea resolves to ≤ grade 1<sup>b</sup> or baseline, then resume at the last administered dose. Intensify antidiarrheal regimen and provide fluid replacement.</p>
<p style="text-indent:0em;text-align:left;">If diarrhea recurs, hold pacritinib until resolves to ≤ grade 1<sup>b</sup> or baseline, then resume at 50% of the last administered dose. Concomitant antidiarrheal management is required when restarting pacritinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serious</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Evaluate and manage promptly for signs/symptoms of infection. Use active surveillance and prophylactic antibiotics according to clinical guidelines.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F56651997"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F56638531"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (48%, grades ≥3: 4%), nausea (32%; grades ≥3: 1%), vomiting (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (24%; grades ≥3: 22%), hemorrhage (grades ≥3: 15%; major hemorrhage: 11% to 13%), thrombocytopenia (34%; grades ≥3: 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (4%), prolonged QT interval on ECG (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Squamous cell carcinoma of skin (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (8%), dyspnea (10%), pneumonia (6%), upper respiratory tract infection (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival hemorrhage</p></div>
<div class="block coi drugH1Div" id="F56628762"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of strong CYP3A4 inhibitors or inducers.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F56651982"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac effects: QTc prolongation (&gt;500 msec, or ≥60 msec increase from baseline) has been reported with pacritinib, although torsades de pointes has not. Another Janus-associated kinase (JAK) inhibitor has increased the risk of major adverse cardiac effects, including cardiovascular death, myocardial infarction, and stroke in patients with rheumatoid arthritis (pacritinib is not approved for the treatment of rheumatoid arthritis).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Almost one-half of patients receiving pacritinib in a clinical trial experienced diarrhea; the median time to resolution was 2 weeks. The incidence of diarrhea decreased over time, with over 40% of patients reporting diarrhea in the first 8 weeks of pacritinib, 15% in weeks 8 through 16, and &lt;10% in weeks 16 through 24.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic toxicity: Pacritinib administration may result in worsening thrombocytopenia; dose reduction due to decreasing platelet counts occurred in some patients with preexisting moderate and/or severe thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Serious and fatal hemorrhages have occurred in patients with moderate to severe thrombocytopenia (platelet counts 50,000 to 100,000/mm<sup>3</sup>), as well as with severe thrombocytopenia (platelet counts &lt;50,000/mm<sup>3</sup>). Grade 3 and higher bleeding events (eg, requiring transfusion or invasive intervention) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious bacterial, mycobacterial, fungal, and viral infections may occur in patients treated with JAK inhibitors, including pacritinib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Another JAK inhibitor has been associated with an increased risk of lymphoma and other malignancies (excluding nonmelanoma skin cancer) in patients with rheumatoid arthritis (not an approved indication for pacritinib). Patients who are current or past smokers are at additional increased risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombosis: Another JAK inhibitor has increased the risk of thrombosis (eg, deep venous thrombosis, pulmonary embolism, and arterial thrombosis) in patients with rheumatoid arthritis (pacritinib is not approved for the treatment of rheumatoid arthritis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F56670741"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vonjo: 100 mg [contains gelatin (bovine)]</p></div>
<div class="block geq drugH1Div" id="F56670739"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56695239"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vonjo Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $258.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F56651977"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Vonjo is available through specialty pharmacies and distributors. Information regarding access is available from the manufacturer at https://www.ctiaccess.com/pdf/CTI_Access_Distribution_Information.pdf or 1-888-284-3678.</p></div>
<div class="block adm drugH1Div" id="F56652269"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Swallow capsules whole; do not open, break, or chew.</p></div>
<div class="block hazard drugH1Div" id="F56651984"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Pacritinib may cause reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F56628761"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelofibrosis:</b> Treatment of intermediate or high-risk primary or secondary (postpolycythemia vera or postessential thrombocythemia) myelofibrosis in adults with a platelet count &lt;50,000/mm<sup>3</sup>.</p></div>
<div class="block mst drugH1Div" id="F56651975"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pacritinib may be confused with afatinib, baricitinib, ceritinib, dasatinib, entrectinib, fedratinib, gilteritinib, pazopanib, ponatinib, ruxolitinib, tofacitinib, upadacitinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56689949"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F56689946"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Pacritinib may increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Pacritinib may increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Pacritinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Pacritinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Pacritinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Pacritinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Pacritinib may increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OCT1 Substrates (Clinically Relevant with Inhibitors): Pacritinib may increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Pacritinib may increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Pacritinib. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56651979"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Pacritinib has the potential to impair male fertility (based on animal data).</p></div>
<div class="block pri drugH1Div" id="F56651980"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">In animal reproduction studies, administration of pacritinib to pregnant mice or rabbits at doses lower than the recommended human dose produced maternal toxicity, embryo, and fetal loss.</p></div>
<div class="block brc drugH1Div" id="F56651981"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pacritinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during therapy and for 2 weeks after the last pacritinib dose.</p></div>
<div class="block mop drugH1Div" id="F56652271"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">CBC (including WBC differential and platelets) and coagulation parameters (prothrombin time, partial thromboplastin time, thrombin time, and INR) periodically, as clinically indicated. Obtain a baseline ECG prior to pacritinib initiation, and as clinically necessary. Monitor for signs/symptoms of hemorrhage/bleeding, diarrhea, QTc prolongation, major adverse cardiovascular events, thrombosis, and infection (use active surveillance and prophylactic antibiotics according to clinical guidelines). Monitor for secondary malignancies (particularly in patients with a known malignancy [other than a successfully treated non-melanoma skin cancer], and patients who are current or past smokers). Monitor adherence.</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F56651986"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pacritinib is a kinase inhibitor with activity against wild-type Janus-associated kinase 2 (JAK2), mutated JAK2<sup>(V617F)</sup>, FMS-like tyrosine kinase 3 (FLT3), interleukin 1 receptor associated kinase-1 (IRAK1), and activin A receptor, type 1/activin receptor like-kinase 2 (ACVR1/ALK2). Pacritinib is selective for JAK2, with higher inhibitory activity for JAK2 (versus JAK3 and TYK2); pacritinib does not inhibit JAK1 at clinically relevant concentrations. Abnormal JAK2 activation is associated with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera.</p></div>
<div class="block phk drugH1Div" id="F56651987"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub> (median): 229 L (range: 156 to 591 L).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A4; forms 2 major metabolites (M1 and M2).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~28 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 87%; Urine: 6% (&lt;1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: ~2.1 L/hour.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74:92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics (AAP) Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pacritinib-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pacritinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522138">
<a name="29522138"></a>Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib versus best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. <i>JAMA Oncol.</i> 2018;4(5):652-659. doi:10.1001/jamaoncol.2017.5818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pacritinib-drug-information/abstract-text/29522138/pubmed" id="29522138" target="_blank">29522138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161" target="_blank">https://www.cdc.gov/niosh/docs/2016-161</a>. Updated September 2016. Accessed March 3, 2022.</div>
</li>
<li>
<div class="reference">
                  Vonjo (pacritinib) [prescribing information]. Seattle, WA: CTI BioPharma Corp; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pacritinib-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 135089 Version 45.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
